Graham Corporation has reversed sharply since the June 8 selloff, gaining 13% on the week to $113.45 — a clean post-earnings relief rally that has left short sellers underwater and options hedges expired worthless.
The positioning setup is now running in the opposite direction from where it stood a week ago. Short interest, which had been building at an alarming pace — up roughly 49% over the past month — ticked fractionally lower on June 16 to 4.3% of the free float. That's still the highest accumulation seen in the period, but the weekly rate of change (up 7.4%) suggests shorts added through the earnings dip rather than into the recovery. The borrow market remains extremely loose: availability is at 1,314%, meaning there are roughly 13 shares available to borrow for every one already shorted. Cost to borrow ticked up 14% on the week to just 0.49% — still negligible, and no squeeze pressure is present. Options positioning has shifted too. The put/call ratio eased to 0.229, about one standard deviation above its 20-day mean of 0.176 — more cautious than the historical norm, but far from the four-standard-deviation spike that preceded the June 8 selloff. The hedging panic is over; the market is recalibrating.
The Street was already leaning constructive heading into the print, and the earnings reaction has broadly validated that tilt. Oppenheimer raised its target to $110 from $100 on June 9, maintaining its Outperform rating — though the stock has now traded through that target, closing at $113.45. The mean analyst target of $112.75 is similarly below the current price, which suggests the Street is yet to fully re-rate following what the company described as strong Q3 earnings growth: revenue up 18% year-over-year with expanding operating margins and a solid defense backlog. The forward-looking EPS factor score is striking — ranking in the 99th percentile for 12-month forward year-on-year EPS growth. That figure has been the engine behind the re-rating and is the number worth watching for any revision. EV/EBITDA has expanded to roughly 30x, up about 1.4 turns over the past month, reflecting the premium the market is now prepared to pay for GHM's defense and aerospace exposure.
Insider activity adds a useful counterpoint. On June 8 — the very day the stock dropped 11% to $95.34 — CEO Daniel Thoren sold 8,095 shares for approximately $772,000, and CFO Christopher Thome sold 3,193 shares for $304,000. Both sales came alongside routine equity award grants, so the context matters: these look like planned award-and-sell sequences rather than conviction sales. Net insider activity over the past 90 days is actually positive at roughly 20,600 shares, though net dollar value is negative after accounting for the sales. Brandes Investment Partners remains the largest external holder at just over 10% of shares, with no reported change in the most recent filing.
The June 18 earnings event — tomorrow morning — is the immediate focus. The prior session (June 8) saw the stock fall 6.4% on the day but recover to a flat 5-day performance, a pattern that suggests the initial print reaction can be sharp and short-lived. GHM now heads into that event at a fresh high, with analysts yet to lift targets above the current price and short sellers sitting on week-old losses — the degree to which the post-print consensus holds above $110 will tell much of the story about whether the current re-rating has legs.
See the live data behind this article on ORTEX.
Open GHM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
